keyword
MENU ▼
Read by QxMD icon Read
search

alzheimer's disease AND imaging

keyword
https://www.readbyqxmd.com/read/28749356/improving-alzheimeres-disease-classification-by-combining-multiple-measures
#1
Jin Liu, Jianxin Wang, Zhenjun Tang, Bin Hu, Fang-Xiang Wu, Yi Pan
Several anatomical magnetic resonance imaging (MRI) markers for Alzheimer's disease (AD) have been identified. Cortical gray matter volume, cortical thickness, and subcortical volume have been used successfully to assist the diagnosis of Alzheimer's disease (AD) including its early warning and developing stages, e.g., mild cognitive impairment (MCI) including MCI converted to AD (MCIc) and MCI not converted to AD (MCInc). Currently, these anatomical MRI measures have mainly been used separately. Thus, the full potential of anatomical MRI scans for AD diagnosis might not yet have been used optimally...
July 25, 2017: IEEE/ACM Transactions on Computational Biology and Bioinformatics
https://www.readbyqxmd.com/read/28747523/-18-f-flortaucipir-pet-mri-correlations-in-non-amnestic-and-amnestic-variants-of-alzheimer-disease
#2
Ilya M Nasrallah, Yin Jie Chen, Meng-Kang Hsieh, Jeffrey S Philips, Kylie Ternes, Grace Stockbower, Yvette Sheline, Corey T McMillan, Murray Grossman, David A Wolk
Non-amnestic Alzheimer disease (AD) variants, including posterior cortical atrophy (PCA) and logopenic variant of primary progressive aphasia (lvPPA), differ in distributions of tau aggregates and neurodegeneration compared to amnestic AD. We evaluated whether (18)F-flortaucipir (also called (18)F-AV-1451) Positron Emission Tomography (PET), targeting tau aggregates, detects these differences and compared this to magnetic resonance imaging (MRI) measures of gray matter (GM) atrophy. Methods: 5 PCA, 4 lvPPA, 6 age-matched AD, and 6 control subjects underwent (18)F-flortaucipir PET and MRI...
July 26, 2017: Journal of Nuclear Medicine: Official Publication, Society of Nuclear Medicine
https://www.readbyqxmd.com/read/28745939/reduced-pineal-volume-in-alzheimer-disease-a-retrospective-cross-sectional-mr-imaging-study
#3
Teruyuki Matsuoka, Ayu Imai, Hiroshi Fujimoto, Yuka Kato, Keisuke Shibata, Kaeko Nakamura, Hajime Yokota, Kei Yamada, Jin Narumoto
Purpose To evaluate pineal volume in patients with Alzheimer disease (AD), patients with mild cognitive impairment (MCI), and healthy control subjects and to correlate the findings with results of cognitive testing and brain parenchymal volumes. Materials and Methods The ethics committee approved this retrospective study. The participants included 63 patients with AD, 33 patients with MCI, and 24 healthy control subjects. There were 36 men and 84 women, with a mean age (±standard deviation) of 76.7 years ± 7...
July 26, 2017: Radiology
https://www.readbyqxmd.com/read/28745443/discrimination-between-patients-with-mild-alzheimer-s-disease-and-healthy-subjects-based-on-cerebral-blood-flow-images-of-the-lateral-views-in-xenon-enhanced-computed-tomography
#4
Shigeru Sase, Homaro Yamamoto, Ena Kawashima, Xin Tan, Yutaka Sawa
BACKGROUND: Quantitative cerebral blood flow (CBF) measurement is expected to help early detection of functional abnormalities caused by Alzheimer's disease (AD) and enable AD treatment to begin in its early stages. Recently, a technique of layer analysis was reported that allowed CBF to be analyzed from the outer to inner layers of the brain. The aim of this work was to develop methods for discriminating between patients with mild AD and healthy subjects based on CBF images of the lateral views created with the layer analysis technique in xenon-enhanced computed tomography...
July 26, 2017: Psychogeriatrics: the Official Journal of the Japanese Psychogeriatric Society
https://www.readbyqxmd.com/read/28741694/reduced-parahippocampal-volume-and-psychosis-symptoms-in-alzheimer-s-disease
#5
Emma McLachlan, Jennifer Bousfield, Robert Howard, Suzanne Reeves
OBJECTIVE: Establishing structural imaging correlates of psychosis symptoms in Alzheimer's disease (AD) could localise pathology and target symptomatic treatment. This study investigated whether psychosis symptoms are associated with visuoperceptual or frontal networks, and whether regional brain volume differences could be linked with the paranoid (persecutory delusions) or misidentification (misidentification phenomena and/or hallucinations) subtypes. METHODS: A total of 104 patients with probable AD (AddNeuroMed; 47 psychotic, 57 non-psychotic), followed up for at least one year with structural MRI at baseline...
July 25, 2017: International Journal of Geriatric Psychiatry
https://www.readbyqxmd.com/read/28740390/brain-regions-associated-with-anosognosia-for-memory-disturbance-in-alzheimer-s-disease-a-magnetic-resonance-imaging-study
#6
Hiroshi Fujimoto, Teruyuki Matsuoka, Yuka Kato, Keisuke Shibata, Kaeko Nakamura, Kei Yamada, Jin Narumoto
BACKGROUND AND OBJECTIVE: Patients with Alzheimer's disease (AD) are frequently unaware of their cognitive symptoms and medical diagnosis. The term "anosognosia" is used to indicate a general lack of awareness of one's disease or disorder. The neural substrate underlying anosognosia in AD is unclear. Since anosognosia for memory disturbance might be an initial sign of AD, it is important to determine the neural correlates. This study was designed to investigate the characteristics and neural correlates of anosognosia for memory disturbance in patients with mild AD...
2017: Neuropsychiatric Disease and Treatment
https://www.readbyqxmd.com/read/28739324/reaction-based-small-molecule-fluorescent-probes-for-dynamic-detection-of-ros-and-transient-redox-changes-in-living-cells-and-small-animals
#7
REVIEW
Rui Lü
Dynamic detection of transient redox changes in living cells and animals has broad implications for human health and disease diagnosis, because intracellular redox homeostasis regulated by reactive oxygen species (ROS) plays important role in cell functions, normal physiological functions and some serious human diseases (e.g., cancer, Alzheimer's disease, diabetes, etc.) usually have close relationship with the intracellular redox status. Small-molecule ROS-responsive fluorescent probes can act as powerful tools for dynamic detection of ROS and redox changes in living cells and animals through fluorescence imaging techniques; and great advances have been achieved recently in the design and synthesis of small-molecule ROS-responsive fluorescent probes...
July 21, 2017: Journal of Molecular and Cellular Cardiology
https://www.readbyqxmd.com/read/28738187/presymptomatic-atrophy-in-autosomal-dominant-alzheimer-s-disease-a%C3%A2-serial-mri-study
#8
Kirsi M Kinnunen, David M Cash, Teresa Poole, Chris Frost, Tammie L S Benzinger, R Laila Ahsan, Kelvin K Leung, M Jorge Cardoso, Marc Modat, Ian B Malone, John C Morris, Randall J Bateman, Daniel S Marcus, Alison Goate, Stephen Salloway, Stephen Correia, Reisa A Sperling, Jasmeer P Chhatwal, Richard Mayeux, Adam M Brickman, Ralph N Martins, Martin R Farlow, Bernardino Ghetti, Andrew J Saykin, Clifford R Jack, Peter R Schofield, Eric McDade, Michael W Weiner, John M Ringman, Paul M Thompson, Colin L Masters, Christopher C Rowe, Martin N Rossor, Sebastien Ourselin, Nick C Fox
INTRODUCTION: Identifying at what point atrophy rates first change in Alzheimer's disease is important for informing design of presymptomatic trials. METHODS: Serial T1-weighed magnetic resonance imaging scans of 94 participants (28 noncarriers, 66 carriers) from the Dominantly Inherited Alzheimer Network were used to measure brain, ventricular, and hippocampal atrophy rates. For each structure, nonlinear mixed-effects models estimated the change-points when atrophy rates deviate from normal and the rates of change before and after this point...
July 21, 2017: Alzheimer's & Dementia: the Journal of the Alzheimer's Association
https://www.readbyqxmd.com/read/28737945/preliminary-pet-study-of-18-f-fc119s-in-normal-and-alzheimer-s-disease-models
#9
Se Jong Oh, Min Hwan Kim, Sang Jin Han, Kyung Jun Kang, In Ok Ko, YoungSoo Kim, Ji Ae Park, Jae Yong Choi, Kyo Chul Lee, Dae Yoon Chi, Yong Jin Lee, Kyeong Min Kim
To evaluate the efficacy of (18)F-FC119S as a positron emission tomography (PET) radiopharmaceutical for the imaging of Alzheimer's disease (AD), we studied the drug absorption characteristics and (18)F-FC119S distribution in normal mice. In addition, we evaluated the specificity of (18)F-FC119S for β-amyloid (Aβ) in the AD group of an APP/PS1 mouse model and compared it with that in the wild-type (WT) group. (18)F-FC119S exhibited the characteristics of rapid brain uptake and washout patterns in the normal mice...
July 24, 2017: Molecular Pharmaceutics
https://www.readbyqxmd.com/read/28737890/a-difluoroboron-%C3%AE-diketonate-probe-shows-turn-on-near-infrared-fluorescence-specific-for-tau-fibrils
#10
Kwang-Su Park, Mi Kyoung Kim, Yujin Seo, Taewoong Ha, Kyeongha Yoo, Seung Jae Hyeon, Yu Jin Hwang, Junghee Lee, Hoon Ryu, Hyunah Choo, Youhoon Chong
Tau aggregation in neuronal cells has recently received significant attention as a robust predictor of the progression of Alzheimer's disease (AD) because of its proven correlation with the degree of cognitive impairment in AD patients. Accordingly, noninvasive imaging of tau aggregates has been highlighted as a promising diagnostic tool for AD. We have previously identified a tau-specific "turn-on" near-infrared fluorescent (NIRF) probe (1), and, in this study, structural modification was performed to optimize its physicochemical as well as fluorescence properties...
July 26, 2017: ACS Chemical Neuroscience
https://www.readbyqxmd.com/read/28737295/towards-a-unified-analysis-of-brain-maturation-and-aging-across-the-entire-lifespan-a-mri-analysis
#11
Pierrick Coupé, Gwenaelle Catheline, Enrique Lanuza, José Vicente Manjón
There is no consensus in literature about lifespan brain maturation and senescence, mainly because previous lifespan studies have been performed on restricted age periods and/or with a limited number of scans, making results instable and their comparison very difficult. Moreover, the use of nonharmonized tools and different volumetric measurements lead to a great discrepancy in reported results. Thanks to the new paradigm of BigData sharing in neuroimaging and the last advances in image processing enabling to process baby as well as elderly scans with the same tool, new insights on brain maturation and aging can be obtained...
July 24, 2017: Human Brain Mapping
https://www.readbyqxmd.com/read/28736899/trajectories-of-depressive-and-anxiety-symptoms-in-older-adults-a-6-year-prospective-cohort-study
#12
Sophie E Holmes, Irina Esterlis, Carolyn M Mazure, Yen Ying Lim, David Ames, Stephanie Rainey-Smith, Chris Fowler, Kathryn Ellis, Ralph N Martins, Olivier Salvado, Vincent Doré, Victor L Villemagne, Christopher C Rowe, Simon M Laws, Colin L Masters, Robert H Pietrzak, Paul Maruff
OBJECTIVE: Depressive and anxiety symptoms are common in older adults, significantly affect quality of life, and are risk factors for Alzheimer's disease. We sought to identify the determinants of predominant trajectories of depressive and anxiety symptoms in cognitively normal older adults. METHOD: Four hundred twenty-three older adults recruited from the general community underwent Aβ positron emission tomography imaging, apolipoprotein and brain-derived neurotrophic factor genotyping, and cognitive testing at baseline and had follow-up assessments...
July 24, 2017: International Journal of Geriatric Psychiatry
https://www.readbyqxmd.com/read/28736311/imaging-wide-association-study-integrating-imaging-endophenotypes-in-gwas
#13
Zhiyuan Xu, Chong Wu, Wei Pan
A new and powerful approach, called imaging-wide association study (IWAS), is proposed to integrate imaging endophenotypes with GWAS to boost statistical power and enhance biological interpretation for GWAS discoveries. IWAS extends the promising transcriptome-wide association study (TWAS) from using gene expression endophenotypes to using imaging and other endophenotypes with a much wider range of possible applications. As illustration, we use gray-matter volumes of several brain regions of interest (ROIs) drawn from the ADNI-1 structural MRI data as imaging endophenotypes, which are then applied to the individual-level GWAS data of ADNI-GO/2 and a large meta-analyzed GWAS summary statistics dataset (based on about 74,000 individuals), uncovering some novel genes significantly associated with Alzheimer's disease (AD)...
July 20, 2017: NeuroImage
https://www.readbyqxmd.com/read/28735012/fgwas-functional-genome-wide-association-analysis
#14
Chao Huang, Paul Thompson, Yalin Wang, Yang Yu, Jingwen Zhang, Dehan Kong, Rivka R Colen, Rebecca C Knickmeyer, Hongtu Zhu
Functional phenotypes (e.g., subcortical surface representation), which commonly arise in imaging genetic studies, have been used to detect putative genes for complexly inherited neuropsychiatric and neurodegenerative disorders. However, existing statistical methods largely ignore the functional features (e.g., functional smoothness and correlation). The aim of this paper is to develop a functional genome-wide association analysis (FGWAS) framework to efficiently carry out whole-genome analyses of functional phenotypes...
July 19, 2017: NeuroImage
https://www.readbyqxmd.com/read/28734961/radix-puerariae-modulates-glutamatergic-synaptic-architecture-and-potentiates-functional-synaptic-plasticity-in-primary-hippocampal-neurons
#15
Mohammad Maqueshudul Haque Bhuiyan, Md Nazmul Haque, Md Mohibbullah, Yung Kyu Kim, Il Soo Moon
ETHNOPHARMACOLOGICAL RELEVANCE: Neurologic disorders are frequently characterized by synaptic pathology, including abnormal density and morphology of dendritic spines, synapse loss, and aberrant synaptic signaling and plasticity. Therefore, to promote and/or protect synapses by the use of natural molecules capable of modulating neurodevelopmental events, such as, spinogenesis and synaptic plasticity, could offer a preventive and curative strategy for nervous disorders associated with synaptic pathology...
July 19, 2017: Journal of Ethnopharmacology
https://www.readbyqxmd.com/read/28733961/a-review-of-biomarkers-for-neurodegenerative-disease-will-they-swing-us-across-the-valley
#16
REVIEW
Thomas G Beach
Measures of the severity of cognitive impairment or parkinsonism are the usual endpoints in clinical trials for Alzheimer's disease (AD) and Parkinson's disease (PD), but are critically hampered by their lack of disease sensitivity and specificity. Due to the high failure rate of clinical trials, the rate of regulatory approval for efficacious new drugs has stagnated in the past few decades, with the gap between basic science discovery and clinical application metaphorically termed the "Valley of Death". While the causes for this are probably multiple and complex, the usage of biomarkers as surrogate endpoints, particularly when they are molecularly-specific for the disease, has achieved some success in cancer trials, and it is likely that neurodegenerative disease trials would benefit from the same approach...
July 2017: Neurology and Therapy
https://www.readbyqxmd.com/read/28733959/increasing-precision-of-clinical-diagnosis-of-alzheimer-s-disease-using-a-combined-algorithm-incorporating-clinical-and-novel-biomarker-data
#17
REVIEW
Marwan N Sabbagh, Lih-Fen Lue, Daniel Fayard, Jiong Shi
Establishing the in vivo diagnosis of Alzheimer's disease (AD) or other dementias relies on clinical criteria; however, the accuracy of these criteria can be limited. The diagnostic accuracy is 77% for a clinical diagnosis of AD, even among experts. We performed a review through PubMed of articles related to specific diagnostic modalities, including APOE genotyping, cerebrospinal fluid (CSF) testing, fludeoxyglucose F 18 positron emission tomography (PET), amyloid PET, tau PET, computed tomography (CT), single-photon emission CT, magnetic resonance imaging (MRI), and B12 and thyroid-stimulating hormone screening, to determine the specificity and sensitivity of each test used in the clinical diagnosis of AD...
July 2017: Neurology and Therapy
https://www.readbyqxmd.com/read/28733957/a-review-of-biomarkers-for-alzheimer-s-disease-in-down-syndrome
#18
REVIEW
Ni-Chung Lee, Yin-Hsiu Chien, Wuh-Liang Hwu
Down syndrome (Trisomy 21; DS) is a unique disease known to be associated with early-onset Alzheimer's disease (AD). The initial presentation of AD in DS is usually difficult to recognize, owing to the underlying intellectual disabilities. Using biomarkers as a prediction tool for detecting AD in at-risk people with DS may benefit patient care. The objective of this review is to discuss the utility of biomarkers in DS on the basis of the pathophysiology of the disease and to provide an update on recent studies in this field...
July 2017: Neurology and Therapy
https://www.readbyqxmd.com/read/28732595/probabilistic-modeling-of-anatomical-variability-using-a-low-dimensional-parameterization-of-diffeomorphisms
#19
Miaomiao Zhang, William M Wells, Polina Golland
We present an efficient probabilistic model of anatomical variability in a linear space of initial velocities of diffeomorphic transformations and demonstrate its benefits in clinical studies of brain anatomy. To overcome the computational challenges of the high dimensional deformation-based descriptors, we develop a latent variable model for principal geodesic analysis (PGA) based on a low dimensional shape descriptor that effectively captures the intrinsic variability in a population. We define a novel shape prior that explicitly represents principal modes as a multivariate complex Gaussian distribution on the initial velocities in a bandlimited space...
July 8, 2017: Medical Image Analysis
https://www.readbyqxmd.com/read/28731438/evidence-that-the-human-innate-immune-peptide-ll-37-may-be-a-binding-partner-of%C3%A2-amyloid-%C3%AE-and-inhibitor-of%C3%A2-fibril-assembly
#20
Ersilia De Lorenzi, Marcella Chiari, Raffaella Colombo, Marina Cretich, Laura Sola, Renzo Vanna, Paola Gagni, Federica Bisceglia, Carlo Morasso, Jennifer S Lin, Moonhee Lee, Patrick L McGeer, Annelise E Barron
BACKGROUND: Identifying physiologically relevant binding partners of amyloid-β (Aβ) that modulate in vivo fibril formation may yield new insights into Alzheimer's disease (AD) etiology. Human cathelicidin peptide, LL-37, is an innate immune effector and modulator, ubiquitous in human tissues and expressed in myriad cell types. OBJECTIVE: We present in vitro experimental evidence and discuss findings supporting a novel hypothesis that LL-37 binds to Aβ42 and can modulate Aβ fibril formation...
July 18, 2017: Journal of Alzheimer's Disease: JAD
keyword
keyword
63770
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"